Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Lococo, S, Covens, A, Carney, M, Franssen, E, Dogde, R, Rosen, B, Osborne, R, Kerr, I, Buckman, R, Soper, J, Rodriguez, G, Depetrillo, A, Clarke-Pearson, D, and Berchuck, A. "Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study." Gynecologic Oncology 59, no. 2 (1995): 194-199.

Full Text

Bast, RC, Boyer, CM, Xu, FJ, Wiener, J, Dabel, R, Woolas, R, Jacobs, I, and Berchuck, A. "Molecular approaches to prevention and detection of epithelial ovarian cancer." J Cell Biochem Suppl 23 (1995): 219-222. (Review)

Scholars@Duke

Berchuck, A, and Boyd, J. "Molecular basis of endometrial cancer." Cancer 76, no. 10 SUPPL. (1995): 2034-2040.

Scholars@Duke

Liu, JR, Conaway, M, Rodriguez, GC, Soper, JT, Clarke-Pearson, DL, and Berchuck, A. "Relationship between race and interval to treatment in endometrial cancer." Obstetrics and Gynecology 86, no. 4 PART 1 (1995): 486-490.

Full Text

Soper, JT, Evans, AC, Conaway, MR, Clarke-Pearson, DL, Berchuck, A, and Hammond, CB. "Evaluation of prognostic factors and staging in gestational trophoblastic tumor." Obstet Gynecol 84, no. 6 (December 1994): 969-973.

Scholars@Duke

CREASMANMD, W. "Second-Look Laparotomy in Ovarian Cancer." Gynecologic Oncology 55, no. 3 (December 1994): S122-S127.

Full Text

Elbendary, A, Berchuck, A, Davis, P, Havrilesky, L, Bast, RC, Iglehart, JD, and Marks, JR. "Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells." Cell Growth Differ 5, no. 12 (December 1994): 1301-1307.

Scholars@Duke

Rodriguez, GC, Hughes, CL, Soper, JT, Berchuck, A, Clarke-Pearson, DL, and Hammond, CB. "Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia." Obstet Gynecol 84, no. 5 (November 1994): 794-797.

Scholars@Duke

Futreal, PA, Liu, Q, Shattuck-Eidens, D, Cochran, C, Harshman, K, Tavtigian, S, Bennett, LM, Haugen-Strano, A, Swensen, J, and Miki, Y. "BRCA1 mutations in primary breast and ovarian carcinomas." Science (New York, N.Y.) 266, no. 5182 (October 1994): 120-122.

Full Text

Soper, JT, Clarke-Pearson, DL, Berchuck, A, Rodriguez, G, and Hammond, CB. "5-day methotrexate for women with metastatic gestational trophoblastic disease." Gynecol Oncol 54, no. 1 (July 1994): 76-79.

Full Text

Pages